

# Angiotensin II and Aging

Manuel Martínez-Maldonado, León F. Ferder

Departments of Physiology, Pharmacology and Medicine.  
Ponce School of Medicine. Ponce, Puerto Rico.

## INTRODUCTION

Organ malfunction is an inevitable result of the natural process of aging which all species undergo. Modifications in organ structure directly related to aging cause functional deterioration of varying degrees in humans by, among other things, leading to replacement of functional parenchyma by fibro-connective tissues and induction of arteriosclerosis in the blood vessels of several organs. Age related changes in kidney function, including its role as an endocrine organ, have been recognized since the seventies. These changes include alterations in the regulation of the renin-angiotensin system (decreased renin production and secretion), and in the endocrine and paracrine functions of their product angiotensin II (All), both of which are dependent on angiotensin II receptors<sup>1,2</sup>. We advance herein the hypothesis that aging, and possibly hypertension and its consequences, including cardiac hypertrophy, result from actions of All.

## ANGIOTENSIN RECEPTORS

The AT<sub>1</sub> receptor belongs to the G protein-coupled receptor superfamily and has been cloned and characterized<sup>3,4</sup>. The AT<sub>1</sub> receptor is considered to be the mediator for the cardiovascular and renal effects of All in normal and, possibly, aging subjects. In contrast, the role, if any, of the AT<sub>2</sub> receptor, highly expressed in growing tissues, in the cardiovascular changes in normal and aging subjects, remains unclear<sup>5-7</sup>. All receptors show a great variability and can be detected in a wide variety of tissues. It is difficult, therefore, to relate them to primary hypertension and their role has not been extensively explored in the aging process. Two AT<sub>1</sub> receptor subtypes appear to exist in rodents, the AT<sub>1A</sub> and AT<sub>1B</sub> which exhibit highly homologous sequences and similar binding and functional characteristics<sup>8</sup>. AT<sub>1A</sub> expression is by far the dominant form in liver, kidney, vasculature and heart whereas the AT<sub>1B</sub> is expressed predominantly in the adrenal gland, uterus and anterior pituitary gland<sup>9</sup>. Both are down-regulated by All.

Complementary mechanisms exist for All down regulation of the cardiac AT<sub>1</sub> gene *in vitro* via calcium- and cAMP-dependent mechanisms.

---

Received for publication: 29/03/2006  
Accepted: 19/06/2006

Such a downregulation of the receptor gene by its agonist is consistent with other members of the G-protein coupled family of receptors. The  $AT_2$  receptor, however, does not appear to be G-protein coupled and possibly signals through phosphotyrosine phosphatase<sup>10</sup>. All receptor subtypes have been characterized in cardiac and renal tissue. The  $AT_{1A}$  and  $AT_{1B}$  receptors presents highly homologous sequences, and similar binding and functional characteristics<sup>3, 8, 11</sup>. In the rat heart, levels of both  $AT_1$  and  $AT_2$  receptor expression are increased during the neonatal period and decrease with maturation<sup>6, 12</sup>.

This family of receptors typically responds to long-term agonist binding with a decrease in receptor number and mRNA levels<sup>13-16</sup>. All treated mesangial cells also demonstrate a dose-dependent decrease in  $AT_1$  mRNA levels similar to that seen in cardiocytes and fibroblasts, whereas in some studies All infused *in vivo* had no effect on the  $AT_1$  mRNA levels in the rat kidney or aorta, although mRNA levels were increased in the adrenal gland<sup>17, 18</sup>. By contrast, in models of experimental ureteral obstruction<sup>19, 20</sup>, which leads to high intrarenal levels of All,  $AT_1$  mRNA levels are downregulated, and this downregulation is partially reversed by angiotensin I converting inhibitors (ACEI) and angiotensin II receptor antagonists (AIIIRA), suggesting that All participates in gene regulation and the underlying pathophysiological conditions may determine the nature of the relationship between the peptide and the expression of the gene for its receptor. Moreover, in ureteral obstruction, both glomerular, and tubular cells exhibit the changes in  $AT_1$  mRNA levels. This tissue- and cell-specific regulation of the  $AT_1$  gene likely speaks to the potential differences in the role of All in different segments of various tissues<sup>21</sup>.

The high susceptibility of cardiomyocytes to the effects of All and aging may be the result of

the density of receptors at this site. Quantitative PCR studies in the rat have found that both  $AT_1$  receptor subtypes are present in the heart with  $AT_{1A}$  mRNA levels three-fold higher than  $AT_{1B}$ <sup>22</sup>.

Analysis of both the number and binding affinity of specific receptors appears to be important in understanding the pathophysiological role of the renin-angiotensin system and in the potential role of All in the heart and kidney in hypertension and aging. Nevertheless, as already mentioned, variation in All receptor expression, complicates the design of studies relating it to primary hypertension, while studies of its potential role in aging are just beginning to emerge<sup>23, 24</sup>.

## ANGIOTENSIN II AND REACTIVE OXYGEN SPECIES IN AGING

Experimental findings indicate that hypertension and aging have similar effects on the structure and function of blood vessels, the heart and, presumably, the kidney. Both conditions also lead to endothelial dysfunction, decreased vascular compliance, left ventricular hypertrophy and stiffness. In the normal kidney, despite no change in blood pressure, All leads to the expression of genes of sclerosis-generating cytokines such as transforming growth factor beta ( $TGF\beta 1$ ), platelet-derived growth factors (PDGF) and osteopontin (OPT), all which enhance tissue fibrosis<sup>25</sup>.

Despite the fact that aging is associated with decreased production and secretion of renin, kidneys are more sensitive to the renal vasoconstrictive effects of exogenous All<sup>26</sup> suggesting an increase in receptor number, greater binding affinity of the peptide or diminished metabolism of the peptide-receptor complex. Similar changes might be expected in the aging kidney that could explain why ACEI or AIIIRA mitigate

some of the functional and architectural renal changes observed as age advances.

All has been suggested as a mediator of oxidative stress through the induction of reactive oxygen species (ROS) in aging and in normal animals<sup>27</sup>. Oxidative stress is known to induce apoptosis and activation of the pro-inflammatory transcription factor nuclear factor kappa B (NFkB), whose biologic effects may play a role in the renal damage associated with arterial hypertension<sup>28</sup>. Oxidative stress, fueled in part by All, up-regulates the expression of adhesion molecules, chemoattractant compounds and cytokines<sup>29</sup>.

Mitochondria are a major source of ROS in aging because their mechanisms of defense from normally formed ROS and superoxide become less effective with the aging process. Moreover, excessive respiratory chain superoxide can combine with nitric oxide (NO) produced from mitochondrial nitric oxide synthase (NOS) to induce apoptosis through the formation of peroxynitrate. This potent oxidant can promote cytochrome C release by increasing the permeability of mitochondrial membranes by opening up permeability transition pores<sup>30</sup>. While All contributes to ventricular remodeling by promoting both cardiac hypertrophy and apoptosis, the mechanism underlying the latter phenomenon is poorly understood. One possibility that has been advanced is that All activates NADPH oxidase, generating free radicals that trigger DNA damage and apoptosis<sup>31</sup>. All blockade can protect against both age-related mitochondrial dysfunction and ultrastructural alterations, underscoring the role of RAS in the aging process<sup>27</sup>.

It has been suggested that the adaptor protein p66<sup>Shc</sup> may also be a target for ROS<sup>32</sup>. When this protein is phosphorylated on Ser36 by oxidative stress, it markedly sensitizes cells to apoptosis, because it participates in the phos-

phorylation-induced repression of Forkhead transcription factors that regulate the expression of various antioxidant enzymes<sup>32</sup>. Furthermore, activation of a mitochondrial pool of p66<sup>Shc</sup> leads to enhanced generation of ROS<sup>33</sup>. Although the study did not examine the effect of All on this potential pathway of oxidative damage in aging, it is conceivable that the same mechanism may apply to aging tissues, including the kidney. It is of great interest that p66<sup>Shc</sup> knock-out mice were resistant to the deleterious cardiac effects (remodeling) of sub-pressor doses of All<sup>34</sup>. It remains to be studied whether a similar effect of p66<sup>Shc</sup> occurs in renal tissue.

#### AGING RESPONSE TO ALL BLOCKADE

It has long been recognized that plasma renin and aldosterone level decrease with advancing age. Studies in aging animals indicate that both renal renin formation and release are reduced, and contribute to the fall in plasma renin concentration. The significance of this finding has remained obscure and its complexity is enhanced by the fact that elderly patients develop hypertension, which could be a factor in the reduced activity of the RAS. Even more intriguing are the findings reported by experiments in one of our laboratories in the attempt to explain the importance of falls in circulating levels of renin and angiotensin.

It was found that CF1 mice treated with the angiotensin I converting enzyme blocker Enalapril and Wistar rats treated with an AIIRA exhibited a reduction of age-associated cardiovascular and renal changes, and had increases in the mitochondrial number within cells. This was associated with an increase in survival and lifespan of the animals. The beneficial effect of RAS blockade occurs in spite of the fact that, as reported, plasma renin concentration and intrarenal renin

mRNA is reduced in older animals<sup>35</sup>. It is, however, consistent with an increase in angiotensin II formation or action within the kidney<sup>36</sup>, and supports the concept that the intrarenal RAS is regulated independently of the circulating system in normal and also in aging animals.

Our studies revealed that plasma levels of angiotensin I and angiotensin II were low in control (untreated) aged animals and that, as expected in non-aged normal animals, aged rats receiving AIIRA exhibited elevated levels of plasma renin, AI and AII, an indication that the angiotensin-renin feedback mechanism is intact in aged rats. Aging was accompanied by high glomerular angiotensin II receptor density as demonstrated by autoradiography. By contrast, receptor density was much lower in the interstitium of untreated aged animals, and was lower in both glomeruli and interstitium in the losartan-treated group<sup>37</sup>.

These results strongly suggest that the renin angiotensin system plays an important role in the mechanisms by which aging affects renal function and that an abnormal regulation of angiotensin II receptors may be responsible for the functional alterations of the kidney. Moreover, AI effects through the production of reactive oxygen species and by damage of mitochondrial function can be responsible for these alterations. This hypothesis is supported by our findings that ACE inhibitors and AIIRA decrease tissue oxidative state, improve mitochondrial number and function, leading to higher animal survival and prolonged lifespan (Figure 1).

## VASCULAR AND CARDIAC AII AT<sub>1</sub> AND AT<sub>2</sub> RECEPTORS

The percentages of AT<sub>1</sub> and AT<sub>2</sub> receptors vary depending on the cell type or tissues under consideration. In rat aorta, 60% of the receptors

are AT<sub>1</sub>, whereas in total rat heart, the percentage of AT<sub>1</sub> reaches 90%<sup>38</sup> of the angiotensin receptors. Cardiomyocytes express exclusively the AT<sub>1</sub> subtype<sup>39</sup>, whereas fibroblasts express AT<sub>2</sub> receptor subtype as well<sup>40</sup>. Although it has been suggested that AT<sub>2</sub> receptor activation is involved in the control of cell differentiation, proliferation and apoptosis<sup>41,42</sup>, the possible roles of AT<sub>2</sub> receptors *in vivo* are poorly understood. In addition, their contribution to the pathophysiology of aging remains obscure (see below). Moreover, limited knowledge exists of the state of function and genetic regulation of AT receptors and their subtypes in renal tissues of aging animals.

AI-induced hypertension and associated cardiac hypertrophy are mediated mainly via the AT<sub>1</sub> receptor subtype. That AI mediates vascular smooth muscle cell (VSMC) trophic effect via AT<sub>2</sub> receptor subtype and independently of a pressure-dependent mechanism can be inferred from the finding that AT<sub>2</sub> receptor blockade with PD123319 infusion in AI-treated rats had no significant effect on blood pressure but prevented the development of vascular hypertrophy of both aorta and coronary arteries. In addition, in normotensive rats, treatment with losartan alone had no effect on blood pressure but induced a medial hypertrophy that was prevented by an additional treatment with PD123319 suggesting that the increase in systemic AI concentration, as a result of AT<sub>1</sub> receptor blockade<sup>43</sup> activates the AT<sub>2</sub> receptors and, as a consequence, unmasks their trophic effect. The trophic effect of the AT<sub>2</sub> receptor subtype appears to be specific to VSMCs and independent of whether it is found in conductive (aorta) or resistance (coronary artery) vessels. Also, it has been shown that AT<sub>2</sub> receptors play a major role in myointimal formation after arterial injury<sup>44</sup> and that the expression of AT<sub>2</sub> receptors is increased




Figura 1

in hypertrophied left ventricle<sup>45</sup>. The role, if any, of this interactive regulation between AT<sub>1</sub> and AT<sub>2</sub> receptors in aging tissues (whether accompanied or not by hypertension), particularly the kidney, remains to be established.

The relative abundance of AT<sub>2</sub> subtype receptors in many fetal tissues supports a role of AT<sub>2</sub> during development<sup>46</sup>. Furthermore, a key role for the AT<sub>2</sub> subtype receptor is suggested by several studies that correlate en-

hanced AT<sub>2</sub> receptor expression with cardiovascular system disease states such as diabetes, hypertension and senescence<sup>47-49</sup>. The ability of a tissue to change the expression of AT<sub>1</sub> receptors to AT<sub>2</sub> has been described in experimentally induced vascular injury<sup>21</sup>, suggesting that Ang II may also play a role, through AT<sub>2</sub> receptors, in smooth muscle cell differentiation and proliferation. In addition, Brilla et al.<sup>40</sup> reported that in cultured adult rat cardiac fibro-

blasts All stimulates collagen synthesis by both AT<sub>1</sub> and AT<sub>2</sub> receptors, and that All inhibition of collagenase activity is specifically mediated by the AT<sub>2</sub> subtype receptor.

Chronic pharmacological blockade of AT<sub>2</sub> subtype All receptors has no systemic hemodynamic (arterial pressure, cardiac output, heart rate) either in normotensive rats or in All-induced hypertensive rats, and does not affect the hypertension-induced cardiac hypertrophy<sup>50</sup>. Furthermore, plasma angiotensin II level and aortic reactivity to All are not affected after chronic AT<sub>2</sub> receptor blockade. Chronic blockade of AT<sub>2</sub> receptors antagonizes the vascular growing effects related to long term All injection, whereas blockade of AT<sub>1</sub> receptors does not. The vasotropic effect of All is at least partially mediated via AT<sub>2</sub> receptor subtype in some experimental model of hypertension.

Considering All's role in the induction of cardiac hypertrophy and possibly fibrosis of tissues, such a mechanism to decrease receptor number could be essential for maintaining normal cardiac structure and function. A similar proposal could be marshalled for the kidney. The protective effects of All blockade, by either diminishing its production or its actions, on fibrosis and proliferation is indirect evidence that, despite low angiotensin II production, increased sensitivity of the kidney to the effects of the hormone could mediate the development of fibrosis and tissue damage in aging, hypertension or aging accompanied by hypertension.

### **AGING AND ENHANCED CARDIAC EXPRESSION OF ANGIOTENSIN II RECEPTOR SUBTYPES**

In the heart and the kidney, the presence of angiotensinogen (ANG), renin, and angiotensin-converting enzyme (ACE) suggests local syn-

thesis of All<sup>51,52</sup>. In young adult rats, the myocardium is able to synthesize All from angiotensinogen and angiotensin-converting enzyme<sup>51</sup>, but it has been shown that a several-fold increase in both ANG and ACE mRNA occurs in the aged LV but not in the RV. This suggests that during aging, an activation of cardiac All synthesis may compensate in part for the depression of the circulating RAS. The possibility cannot be discarded that a similar mechanism exists to maintain normal intrarenal resistances and glomerular filtration fraction in the aging kidney.

Although less is known relative to the kidney, senescence is associated with marked changes in cardiac structure and morphology such as cardiomyocyte loss, hypertrophy of the remaining cells, and the development of fibrosis<sup>53,54</sup>. These changes may account for the functional characteristics of the senescent myocardium such as impaired myocardial perfusion<sup>55</sup>, altered diastolic compliance<sup>53</sup>, and arrhythmias<sup>56</sup>. Vascular structures are also modified, and aging is associated with increased arterial wall stiffness, as shown by a significant decrease in systemic and local arterial compliance and an increase in aortic impedance<sup>53,57</sup>, which may induce mild left ventricular hypertrophy. There is now evidence that senescence is associated with increased cardiac ANG and ACE gene expression, suggesting increased cardiac All synthesis, whereas plasma RAS activity, as already mentioned, is largely depressed<sup>58</sup>.

The presumed mechanistic pathways involved in the increase in cardiac All receptor gene expression are multiple. Up-regulation could be intrinsic to the developmental gene reprogramming often associated with senescence. Cardiac senescence is characterized by the reexpression of fetal proteins, such as the contractile protein isoform b-MHC and the

atrial natriuretic peptide gene<sup>59,60</sup>. On the other hand, several studies in rat ventricular tissue have demonstrated developmental regulation of cardiac All receptor subtype densities and gene expression, which are abundant during the neonatal period and decrease with maturation<sup>61-63</sup>. Secondly, humoro-hormonal status is modified during senescence, and is characterized by a large decrease in plasma All synthesis, and an increase in plasma cortisol level<sup>58</sup>. A number of circulating factors, such as vasoactive substances, growth factors, and steroids modulate AT<sub>1</sub> expression via their effects on the transcriptional activity of AT<sub>1</sub> gene<sup>18,64,65</sup>. However, the differential pattern of AT<sub>1</sub> gene expression observed in the LV and RV of aged rats makes a major role of these hormones in the regulation of AT<sub>1</sub> gene expression unlikely.

Much less is known about the hormonal regulation of AT<sub>2</sub>mRNA level. Yet, based on the up-regulation of AT<sub>2</sub> gene expression in both ventricles of aged rats, hormonal and humoral factors might be one of the triggers for the increase in cardiac AT<sub>2</sub> gene expression during senescence. Mechanical factors are repeatedly proposed as triggers for the regulation of genetic expression during the development of cardiac hypertrophy. Activation of AT<sub>1</sub> and/or AT<sub>2</sub> gene expression has been demonstrated in ventricular tissue during haemodynamic overload<sup>66,67</sup>. Mechanical stretch has also been recently shown to up-regulate AT<sub>1</sub> and AT<sub>2</sub> gene expression in neonatal rat cardiac myocytes, the increase in AT<sub>1</sub> gene expression being mainly due to increased transcription, whereas that of AT<sub>2</sub> results from stabilization of AT<sub>2</sub> mRNA metabolism<sup>68</sup>. Even though cardiac output and ejection fraction of both aged human and rat hearts are unaltered, the increase in vascular stiffness and aortic impedance during aging result in a moderate increase in LV

afterload<sup>69,70</sup>. These changes in LV properties might therefore account, at least in part, for the up-regulation of AT<sub>1</sub> gene expression in the LV of aged rats.

Heymes and collaborators<sup>49</sup> have demonstrated increased density of both AT<sub>1</sub> and AT<sub>2</sub> receptors in the LV myocardium of senescent rats and activation of the intracardiac RAS in aging, associated with suppression of plasma All synthesis. Such local and independent regulation of intracardiac All synthesis and receptor subtype expression could account for both autocrine and paracrine actions<sup>71</sup> and support the concept of intracardiac All production as a regulator of cardiac hypertrophy and collagen accumulation; a condition that could also prevail in renal tissues.

A strong correlation between AT<sub>2</sub> gene expression and fibrosis in both ventricles, compared with the correlation of AT<sub>1</sub> and ACE mRNA levels with LV fibrosis only, has suggested<sup>49</sup> that age-associated cardiac fibrosis is more closely related to the AT<sub>2</sub> than the AT<sub>1</sub> receptor subtype. This suggestion is given credence by studies of Lorell *et al.*<sup>72</sup>, who demonstrated that, both AT<sub>1</sub> inhibition and decrease in ACE gene expression affected neither cardiac fibrosis nor hypertrophy in a pressure-overload rat model.

Up-regulation of the cardiac RAS or the intrarenal RAS may, in part, compensate for the large age-related fall in plasma All synthesis. However, activation of local RAS systems and increased expression of All receptor subtypes might have detrimental effects when other pathological manifestations often associated with senescence, such as hypertension, heart failure, tubulointerstitial or glomerular damage, are superimposed. All receptor subtype antagonists could therefore be therapeutically useful in normal elderly people or elderly people with renal disease.

## KIDNEY AII RECEPTORS AS A FUNCTION OF AGE

Studies by Correa and collaborators<sup>73</sup> in immature (1-week-old) and adult (12-week-old) normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) revealed that AII receptors and ACE binding sites, measured by quantitative autoradiography for quantification of AII receptors in both neonatal and adult animals of either strain, were of AT<sub>1</sub> subtype. In all kidney segments of 1-week-old rats AII receptor density was higher in SHR than WKY. Binding density increased with age in WKY rats; thus, in the glomeruli and the outer stripe of the outer medulla of 12-week-old WKY, binding was significantly higher than that present in age-matched SHR. In contrast, [<sup>125</sup>I]351A (an iodotyrosyl derivative of the ACE inhibitor lisinopril that binds specifically to the active site of ACE<sup>74</sup>) was highest in the outer medulla and not detectable in glomeruli. In 1-week-old rats, binding to ACE was higher in WKY than in SHR strain. Differences in ACE binding between adult SHR and WKY rats were inexistent, with the exception of the inner stripe of the outer medulla, where no binding was detected in SHR. These studies suggest that the renal RAS is developmentally regulated and is involved in the genesis and maintenance of genetic hypertension in SHR as aging proceeds. The evolution of the regulation of ACE and the AT<sub>1</sub> and AT<sub>2</sub> receptor beyond 12-weeks of aging and how this evolves in relation to hypertension and renal damage remains to be studied.

An influence of age on the RAS can also be gleaned from studies in male heterozygous transgenic hypertensive rats TGR (mREN2)27 (TGR)<sup>75</sup>. Compared to Sprague-Dawley control rats, receptor density was significantly lower in TGR. Measurement of density and affinity of AII

receptors in glomeruli of animals 11 weeks old as compared to 18-20 weeks old rats revealed that receptor number increased with aging. In renal arteries, the AII receptor mRNA of the main receptor subtype AT<sub>1A</sub> was neither strain nor age dependent, AT<sub>1B</sub>- and AT<sub>2</sub>-receptor mRNAs were significantly lower in TGR than SPRD rats. This study provide evidence that an overactive renin-angiotensin system in TGR rats led to a down-regulation of glomerular angiotensin II receptors that was not accompanied by a down-regulation of the mRNA of the dominant AT<sub>1A</sub>- receptor subtype, particularly as age advanced. Diminished density of AII receptor leading to enhanced sensitivity to AII could explain in part the development of nephrosclerosis and the tubulointerstitial damage seen in these rats, particularly as they age.

### Correspondence to:

M. Martínez-Maldonado, MD  
Ponce School of Medicine  
P.O. Box 7004  
Ponce, Puerto Rico 00732  
mmartinez@psm.edu

### References

1. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. *J Am Geriatr Soc* 1985, 33(4):278-285.
2. Ferder LF, Inserra F, Basso N: Advances in our understanding of aging: role of the renin-angiotensin system. *Curr Opin Pharmacol* 2002, 2(2):189-194.
3. Sandberg K, Ji H, Clark AJ, Shapira H, Catt KJ: Cloning and expression of a novel angiotensin II receptor subtype. *J Biol Chem* 1992, 267(14):9455-9458.
4. Mauzy CA, Hwang O, Egloff AM, Wu LH, Chung FZ: Cloning, expression, and characterization of a gene encoding the human angiotensin II type 1A receptor. *Biochem Biophys Res Commun* 1992, 186(1):277-284.
5. Dudley DT, Panek RL, Major TC, Lu GH, Bruns RF, Klinkefus BA, Hodges JC, Weishaar RE: Subclasses of angiotensin II binding sites and their functional significance. *Mol Pharmacol* 1990, 38(3):370-377.



6. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE: Expression of AT2 receptors in the developing rat fetus. *J Clin Invest* 1991, 88(3):921-933.
7. Naftilan AJ, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. *J Clin Invest* 1989, 83(4):1419-1424.
8. Iwai N, Inagami T: Identification of two subtypes in the rat type I angiotensin II receptor. *FEBS Lett* 1992, 298(2-3):257-260.
9. Iwai N, Inagami T, Ohmichi N, Nakamura Y, Saeki Y, Kinoshita M: Differential regulation of rat AT1a and AT1b receptor mRNA. *Biochem Biophys Res Commun* 1992, 188(1):298-303.
10. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. *J Biol Chem* 1993, 268(33):24543-24546.
11. Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD: Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. *Biochem Biophys Res Commun* 1992, 183(3):1090-1096.
12. Tsutsumi K, Stromberg C, Viswanathan M, Saavedra JM: Angiotensin-II receptor subtypes in fetal tissue of the rat: autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis. *Endocrinology* 1991, 129(2):1075-1082.
13. Bouscarel B, Wilson PB, Blackmore PF, Lynch CJ, Exton JH: Agonist-induced down-regulation of the angiotensin II receptor in primary cultures of rat hepatocytes. *J Biol Chem* 1988, 263(29):14920-14924.
14. Bouvier M, Hnatowich M, Collins S, Kobilka BK, Deblasi A, Lefkowitz RJ, Caron MG: Expression of a human cDNA encoding the beta 2-adrenergic receptor in Chinese hamster fibroblasts (CHW): functionality and regulation of the expressed receptors. *Mol Pharmacol* 1988, 33(2):133-139.
15. Hadcock JR, Malbon CC: Down-regulation of beta-adrenergic receptors: agonist-induced reduction in receptor mRNA levels. *Proc Natl Acad Sci U S A* 1988, 85(14):5021-5025.
16. Collins S, Bouvier M, Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ: Mechanisms involved in adrenergic receptor desensitization. *Biochem Soc Trans* 1990, 18(4):541-544.
17. Makita N, Iwai N, Inagami T, Badr KF: Two distinct pathways in the down-regulation of type-1 angiotensin II receptor gene in rat glomerular mesangial cells. *Biochem Biophys Res Commun* 1992, 185(1):142-146.
18. Iwai N, Inagami T: Regulation of the expression of the rat angiotensin II receptor mRNA. *Biochem Biophys Res Commun* 1992, 182(3):1094-1099.
19. Pimentel JL, Jr., Sundell CL, Wang S, Kopp JB, Montero A, Martinez-Maldonado M: Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. *Kidney Int* 1995, 48(4):1233-1246.
20. Pimentel JL, Jr., Wang S, Martinez-Maldonado M: Regulation of the renal angiotensin II receptor gene in acute unilateral ureteral obstruction. *Kidney Int* 1994, 45(6):1614-1621.
21. Dzau VJ, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. *Hypertension* 1991, 18(4 Suppl):II100-105.
22. Kitami Y, Okura T, Marumoto K, Wakamiya R, Hiwada K: Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. *Biochem Biophys Res Commun* 1992, 188(1):446-452.
23. Crabos M, Bertschin S, Buhler FR, Rogg H, Evequoz D, Eberhard M, Erne P: Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. *J Hypertens Suppl* 1993, 11(5):S230-231.
24. Duggan J, Kilfeather S, O'Brien E, O'Malley K, Nussberger J: Effects of aging and hypertension on plasma angiotensin II and platelet angiotensin II receptor density. *Am J Hypertens* 1992, 5(10):687-693.
25. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, Johnson RJ, Lai KN, Lan HY: Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. *Kidney Int* 2000, 58(4):1469-1480.
26. Baylis C: Renal responses to acute angiotensin II inhibition and administered angiotensin II in the aging, conscious, chronically catheterized rat. *Am J Kidney Dis* 1993, 22(6):842-850.
27. de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Insera F, Ferder L, Fraga CG: Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. *Faseb J* 2003, 17(9):1096-1098.
28. Quiroz Y, Bravo J, Herrera-Acosta J, Johnson RJ, Rodriguez-Iturbe B: Apoptosis and NFkappaB activation are simultaneously induced in renal tubulointerstitium in experimental hypertension. *Kidney Int Suppl* 2003(86):S27-32.
29. Klahr S, Morrissey JJ: The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. *Kidney Int Suppl* 2000, 75:S7-14.
30. Ghafourifar P, Cadenas E: Mitochondrial nitric oxide synthase. *Trends Pharmacol Sci* 2005, 26(4):190-195.
31. Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Schaffer S: Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. *Am J Physiol Heart Circ Physiol* 2003, 285(6):H2364-2372.

32. Purdom S, Chen QM: p66(Shc): at the crossroad of oxidative stress and the genetics of aging. *Trends Mol Med* 2003, 9(5):206-210.
33. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M *et al*: The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. *J Biol Chem* 2004, 279(24):25689-25695.
34. Booz GW: Growing old, angiotensin II, cardiac hypertrophy, and death: making the connection with p66Shc. *Hypertension* 2005, 46(2):259-260.
35. Ferder L, Inserra F, Romano L, Ercole L, Pszeny V: Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. *Am J Physiol* 1993, 265(1 Pt 1):C15-18.
36. Ferder L, Inserra F, Romano L, Ercole L, Pszeny V: Decreased glomerulosclerosis in aging by angiotensin-converting enzyme inhibitors. *J Am Soc Nephrol* 1994, 5(4):1147-1152.
37. Kasper SO, Basso N, Kurnjek ML, Paglia N, Ferrario CM, Ferder LF, Diz DI: Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. *Am J Nephrol* 2005, 25(4):335-341.
38. Lassègue B, Griendling K, Alexander R: Molecular biology of angiotensin II receptors. In: *Angiotensin receptors*. Edited by Saavedra JM, Timmermans PBMWM. New York: Plenum Press; 1994: Chapter 17:17-48.
39. Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM, Homcy CJ, Anversa P: Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. *Circ Res* 1993, 72(6):1149-1162.
40. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. *J Mol Cell Cardiol* 1994, 26(7):809-820.
41. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J Clin Invest* 1995, 95(2):651-657.
42. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. *Proc Natl Acad Sci U S A* 1996, 93(1):156-160.
43. Sabri A, Levy BI, Poitevin P, Caputo L, Faggin E, Marotte F, Rappaport L, Samuel JL: Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. *Arterioscler Thromb Vasc Biol* 1997, 17(2):257-264.
44. Janiak P, Pillon A, Prost JF, Vilaine JP: Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. *Hypertension* 1992, 20(6):737-745.
45. Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tang SS: Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. *Am J Physiol* 1994, 267(2 Pt 2):H844-852.
46. Millan MA, Carvallo P, Izumi S, Zemel S, Catt KJ, Aguilera G: Novel sites of expression of functional angiotensin II receptors in the late gestation fetus. *Science* 1989, 244(4910):1340-1342.
47. Sechi LA, Griffin CA, Schambelan M: The cardiac renin-angiotensin system in STZ-induced diabetes. *Diabetes* 1994, 43(10):1180-1184.
48. Wu JN, Edwards D, Berecek KH: Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. *Hypertension* 1994, 23(6 Pt 2):819-822.
49. Heymes C, Silvestre JS, Llorens-Cortes C, Chevalier B, Marotte F, Levy BI, Swynghedauw B, Samuel JL: Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. *Endocrinology* 1998, 139(5):2579-2587.
50. Wollert KC, Drexler H: The renin-angiotensin system and experimental heart failure. *Cardiovasc Res* 1999, 43(4):838-849.
51. Lindpaintner K, Jin MW, Niedermaier N, Wilhelm MJ, Ganten D: Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. *Circ Res* 1990, 67(3):564-573.
52. Campbell DJ: Circulating and tissue angiotensin systems. *J Clin Invest* 1987, 79(1):1-6.
53. Lakatta EG: Cardiovascular regulatory mechanisms in advanced age. *Physiol Rev* 1993, 73(2):413-467.
54. Besse S, Robert V, Assayag P, Delcayre C, Swynghedauw B: Nonsynchronous changes in myocardial collagen mRNA and protein during aging: effect of DOCA-salt hypertension. *Am J Physiol* 1994, 267(6 Pt 2):H2237-2244.
55. Hachamovitch R, Wicker P, Capasso JM, Anversa P: Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. *Am J Physiol* 1989, 256(1 Pt 2):H66-73.
56. Carre F, Lessard Y, Coumel P, Ollivier L, Besse S, Lecarpentier Y, Swynghedauw B: Spontaneous arrhythmias in various models of cardiac hypertrophy and senescence of rats. A Holter monitoring study. *Cardiovasc Res* 1992, 26(7):698-705.
57. Michel JB, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E, Corman B, Levy BI: Effect of chronic ANG I-

- converting enzyme inhibition on aging processes. II. Large arteries. *Am J Physiol* 1994, 267(1 Pt 2):R124-135.
58. Heymes C, Swynghedauw B, Chevalier B: Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats. *Circulation* 1994, 90(3):1328-1333.
  59. Lompre AM, Mercadier JJ, Schwartz K: Changes in gene expression during cardiac growth. *Int Rev Cytol* 1991, 124:137-186.
  60. Chien KR, Knowlton KU, Zhu H, Chien S: Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. *Faseb J* 1991, 5(15):3037-3046.
  61. Hunt RA, Ciuffo GM, Saavedra JM, Tucker DC: Quantification and localisation of angiotensin II receptors and angiotensin converting enzyme in the developing rat heart. *Cardiovasc Res* 1995, 29(6):834-840.
  62. Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M: Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. *J Clin Invest* 1994, 93(4):1592-1601.
  63. Everett AD, Fisher A, Tufro-McReddie A, Harris M: Developmental regulation of angiotensin type 1 and 2 receptor gene expression and heart growth. *J Mol Cell Cardiol* 1997, 29(1):141-148.
  64. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T: Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. *Hypertension* 1994, 23(1):25-30.
  65. Ullian ME, Schelling JR, Linas SL: Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. *Hypertension* 1992, 20(1):67-73.
  66. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. *J Clin Invest* 1995, 95(1):46-54.
  67. Suzuki J, Matsubara H, Urakami M, Inada M: Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. *Circ Res* 1993, 73(3):439-447.
  68. Kijima K, Matsubara H, Murasawa S, Maruyama K, Mori Y, Ohkubo N, Komuro I, Yazaki Y, Iwasaka T, Inada M: Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. *Circ Res* 1996, 79(4):887-897.
  69. Rodeheffer RJ, Gerstenblith G, Becker LC, Fleg JL, Weisfeldt ML, Lakatta EG: Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. *Circulation* 1984, 69(2):203-213.
  70. Assayag P, Charlemagne D, de Leiris J, Boucher F, Valere PE, Lortet S, Swynghedauw B, Besse S: Senescent heart compared with pressure overload-induced hypertrophy. *Hypertension* 1997, 29(1 Pt 1):15-21.
  71. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. *Annu Rev Physiol* 1992, 54:227-241.
  72. Weinberg EO, Lee MA, Weigner M, Lindpaintner K, Bishop SP, Benedict CR, Ho KK, Douglas PS, Chafizadeh E, Lorell BH: Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. *Circulation* 1997, 95(6):1592-1600.
  73. Correa FM, Viswanathan M, Ciuffo GM, Tsutsumi K, Saavedra JM: Kidney angiotensin II receptors and converting enzyme in neonatal and adult Wistar-Kyoto and spontaneously hypertensive rats. *Peptides* 1995, 16(1):19-24.
  74. Walsh DA, Catravas J, Wharton J: Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis. *Ann Rheum Dis* 2000, 59(2):125-131.
  75. Lemmer B, Rueff T, Reiter S, Huser L, Hauptfleisch S, Witte K: Influence of circadian time and age on glomerular angiotensin II receptors in normotensive Sprague-Dawley and transgenic hypertensive TGR(mREN2)27 rats. *Chronobiol Int* 2001, 18(3):447-459.

